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Aside from its inability to accurately triage patients with
obstructive disease to the interventional laboratory (1), the
noninvasive evaluation of coronary artery disease has been
plagued from its inception by a poorly appreciated, funda-
mental paradox that renders its application to individual
patients problematic. All the technologies used to measure
the signiﬁcance of an angiographic coronary stenosis have
been validated by using the coronary stenosis itself as the
gold standard and have then used the technology to judgeSee page 1145the gold standard from which it was derived (2). For
instance, the sensitivity and speciﬁcity of myocardial perfu-
sion imaging were deﬁned by its ability to identify a >50%
diameter stenosis on coronary angiography. Thus, a normal
scan in the setting of an 80% stenosis is by deﬁnition a false-
negative ﬁnding. However, current clinical practice con-
cludes that the 80% stenosis being evaluated is incapable of
producing ischemia. Which is it: a false-negative result on
myocardial perfusion imaging or a misleading 80% stenosis?
Is an abnormal scan in the setting of apparently normal
coronary arteries a false-positive ﬁnding or evidence of
microvascular ischemia? We cannot have it both ways. This
critique applies as well to electrocardiographic stress testing,
stress echocardiography, positron emission tomography,
magnetic resonance imaging, coronary computed tomogra-
phy angiography (CTA), and CTA perfusion, all of which
were validated by using angiographic stenosis as the gold
standard. The argument of whether function trumps anat-
omy is irrelevant if all are fundamentally ﬂawed.
Critics of this logic would point to the very large databases
demonstrating the prognostic value of each of these tech-
nologies as conﬁrmation of their utility and validity. This
argument reﬂects the viewpoint of “lumpers,” who regard
patients as representatives of a large database, rather than
“splitters,” who appropriately treat them as unique subjects.
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bases is assumed to apply to all patients who have had a normal
study, irrationally equating those with normal coronary ar-
teries to those with left main or triple-vessel disease.
What then is to be used as the gold standard to evaluate
individual patients? Two invasive technologies have been
used: intravascular ultrasound and fractional ﬂow reserve
(FFR). Intravascular ultrasound is subject to the same crit-
icism as the noninvasive technologies: it was validated by
myocardial perfusion imaging and stress echocardiography,
which, as noted earlier, were validated by angiographic
coronary stenosis. FFR, conversely, has become the accepted
gold standard (3,4). Although initially validated by using
myocardial perfusion imaging and stress echocardiography,
it has emerged from the bonds of the paradox to be the ﬁrst
technology to use clinical outcomes, most notably in the
DEFER (A Multicenter Randomized Study to Compare
Deferral Versus Performance of PCI of Non-Ischemia-
Producing Stenoses) and FAME (Fractional Flow Reserve
Versus Angiography in Multivessel Evaluation) studies
(5–7), as its gold standard. Decisions based on speciﬁc FFR
values signiﬁcantly affected patient morbidity and mor-
tality, resulting in the incorporation of FFR-guided inter-
vention for intermediate stenoses into the interventional
guidelines with a recommendation of Class IIa, Level of
Evidence: A (3). However, it is even more invasive than
coronary angiography and is clearly not suitable for routine
patient evaluation.
FFRCT, FFR derived from standard acquired CTA
datasets (HeartFlow, Inc., Redwood City, California), is the
ﬁrst noninvasive test to be validated from its inception by an
outcome-based gold standard; that is, invasive FFR, rather
than one ultimately based on coronary stenosis measure-
ment. The application of computational ﬂuid dynamics
allows for derivation of FFR, based on projected adenosine-
induced vasodilation at any point in the vascular tree, from a
CTA of at least moderate quality acquired at rest, without
adenosine infusion (8). The brief history of FFRCT trials is
summarized in Table 1.
The initial report (DISCOVER-FLOW [Diagnosis of
Ischemia-Causing Stenoses Obtained Via Noninvasive
Fractional Flow Reserve]) was nothing short of spectacular,
with remarkable improvements in speciﬁcity, positive pre-
dictive value, and accuracy with the addition of FFRCT to
CT alone by using invasive FFR as the gold standard, but
it was a single-center study with only 103 patients (9).
The ﬁrst multicenter study (DeFACTO [Determination
of Fractional Flow Reserve by Anatomic Computed
Tomographic Angiography]) was eagerly awaited but proved
to be a disappointment; the addition of FFRCT yielded no
signiﬁcant increases in any parameter (10). Consequently,
for the multicenter study (NXT [Analysis of Coronary
Blood Flow Using CT Angiography: Next Steps]) presented
in this issue of the Journal by Nørgaard et al. (11), the in-
vestigators went to great lengths to correct the perceived
shortcomings of the DeFACTO trial. Improved automated
Table 1
Summary of FFRCT Trials for Detection of
Invasive FFR 0.80
DISCOVER-FLOW (9) DeFACTO (10) NXT (11)
Year 2011 2012 2013
No. 103 252 251
Design Single-center Multicenter Multicenter
CT FFRCT CT FFRCT CT FFRCT
Sensitivity 94% 93% 84% 90% 94% 86%
Speciﬁcity 25% 82% 42% 54% 34% 79%
PPV 58% 85% 61% 67% 40% 65%
NPV 80% 91% 72% 84% 92% 93%
Accuracy 61% 81% 64% 73% 53% 81%
CT ¼ computed tomography; DeFACTO ¼ Determination of Fractional Flow Reserve by Anatomic
Computed Tomographic Angiography; DISCOVER-FLOW ¼ Diagnosis of Ischemia-Causing Stenoses
Obtained Via Noninvasive Fractional Flow Reserve; FFRCT ¼ fractional ﬂow reserve (FFR) derived
from standard acquired computed tomography angiography datasets; NPV ¼ negative predictive
value; NXT ¼ Analysis of Coronary Blood Flow Using CT Angiography: Next Steps; PPV ¼ positive
predictive value.
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1157image processing methods were implemented for better
lumen boundary identiﬁcation; physiological models of
microcirculatory resistance that yielded better diagnostic
performance than the previous studies were used; and strict
adherence to the best practices for image acquisition (in
particular, rate control and nitroglycerin administration) was
mandated. The results reﬂect the remedies: in 484 vessels in
251 patients, the addition of FFRCT to CT dramatically and
signiﬁcantly improved the per-patient speciﬁcity, positive
predictive value, and accuracy for invasive FFR 0.80
(Table 1), and the area under the receiver-operating char-
acteristic curve increased from 0.81 to 0.90 (p ¼ 0.0008).
Similar results were obtained for per-vessel analysis, 30% to
70% stenosis, and for patients with coronary artery calcium
Agatston scores >400. Thus, FFRCT seems poised to as-
sume the role of gatekeeper to the interventional laboratory
for patients with CTA-deﬁned intermediate stenoses, a role
initially envisioned fordbut not fulﬁlled bydCTA alone.
There are numerous issues to be considered:
1. Are there sufﬁcient data to warrant implementation of
this new technology? There have been a total of only
606 patients reported in the literature using FFRCT,
and only the current study (11) of 251 patients used
the latest physiological modeling and improved
automated image processing. As the authors
acknowledge, additional appropriately designed pro-
spective trials are needed. Is it correct to demand
randomized controlled trials (RCTs), similar to
FAME and DEFER (5–7), to prove that FFRCT
improves outcomes, or is a strong correlation with
invasive FFR sufﬁcient? Ironically, there has never
been an RCT demonstrating that any form of
noninvasive testing improves outcomes, yet the
absence of RCTs has been a constant criticism of
coronary CTA and coronary artery calcium scanning.
2. Demonstration of superior cost-effectiveness com-
pared with other noninvasive testing, as well as su-
perior accuracy, will be a prerequisite. Such analyses(12) may already have been or will be presented to
payers, and they will also be instrumental in deter-
mining the level of reimbursement.
3. Will an FFRCT 0.8 be sufﬁcient to proceed with
intervention or will conﬁrmation by invasive FFR be
necessary? The positive predictive value of 65% is not
high enough to preclude the need for conﬁrmation by
invasive FFR. Further improvements in the Heart-
Flow technology or new algorithms from other ven-
dors may render conﬁrmation unnecessary. The
negative predictive value of CTA alone (92%) is high
enough to defer catheterization and is not augmented
by FFRCT.
4. If future studies lend convincing additional support for
FFRCT as the preferred modality, there is likely to be a
devastating impact on all the noninvasive functional
technologies, with expensive, high technology myo-
cardial perfusion imaging bearing the brunt. As long
as invasive FFR reigns supreme, the correlations with
FFRCT remain excellent, and CTA technology con-
tinues to improve as radiation exposure decreases, why
would other tests be used except in those cases not
suitable for CTA (e.g., renal dysfunction, very exces-
sive calciﬁcation)? In turn, the resulting decreased
income from noninvasive testing will accelerate the
rapidly ongoing hospital acquisition of private prac-
tices with all the implications thereof.
5. Succession of invasive FFR to the throne of functional
evaluation is based on several reports in a limited
number of patients. If further studies cast doubt on its
supremacy, CT FFR will suffer accordingly.
6. Logistical issues (i.e., offsite data analysis by Heart-
Flow and the attendant turnaround time) are unlikely
to be problematic for patients in stable condition.
7. There will always be skeptics who will not accept the
derivation of vasodilator parameters without applying
vasodilation itself. However, the data, although
counterintuitively derived, will speak for themselves.
Time will tell whether FFRCT will emerge as the gold
standard of noninvasive functional testing. The initial
experience, however, is promising, and wide acceptance
would indeed be a major “game changer.”
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